Chapter 21: Calcium Channel Blockers

Pharmacology For the Primary Care Provider 4th Edition by Edmunds Mayhew

$2.99

Chapter 21: Calcium Channel Blockers

 

Complete Chapter Questions With Answers

 

Sample Questions Are Posted Below

 

MULTIPLE CHOICE

 

  1. A patient who has stable angina pectoris and a history of previous myocardial infarction takes nitroglycerin and verapamil. The patient asks the primary care nurse practitioner (NP) why it is necessary to take verapamil. The NP should tell the patient that verapamil:
a. improves blood flow and oxygen delivery to the heart.
b. increases the rate of contraction of the cardiac muscle.
c. increases the force of contraction of the cardiac muscle.
d. has a positive inotropic effect to increase cardiac output.

 

 

ANS:  A

Verapamil decreases the force of smooth muscle contraction in the smooth muscle of the coronary and peripheral vessels; this results in coronary artery dilation, which lowers coronary resistance and improves blood flow through collateral vessels as well as oxygen delivery to ischemic areas of the heart. Calcium channel blockers do not increase the rate or force of contraction of the heart.

 

DIF:    Cognitive Level: Applying (Application)                           REF:   265 – 266

 

  1. A patient who takes nitroglycerin for stable angina pectoris develops hypertension. The primary care NP should contact the patient’s cardiologist to discuss adding:
a. amlodipine (Norvasc).
b. diltiazem (Cardizem).
c. verapamil HCl (Calan).
d. nifedipine (Procardia XL).

 

 

ANS:  D

Nifedipine and related drugs are potent vasodilators, which makes them more effective for hypertension than verapamil and diltiazem. Amlodipine is not a first-line drug.

 

DIF:    Cognitive Level: Applying (Application)                           REF:   267

 

  1. A patient who has stable angina is taking nitroglycerin and a b-blocker. The patient tells the primary care NP that the cardiologist is considering adding a calcium channel blocker. The NP should anticipate that the cardiologist will prescribe:
a. isradipine (DynaCirc).
b. nicardipine (Cardene).
c. verapamil HCl (Calan).
d. nifedipine (Procardia XL).

 

 

ANS:  C

Nitrates and b-blockers are first-line therapy for stable angina. Calcium channel blockers should be reserved for patients who cannot take these agents or patients whose symptoms are not controlled with these agents. Verapamil is one of the calcium channel blockers that should be used. The other calcium channel blockers are not recommended for this purpose.

 

DIF:    Cognitive Level: Applying (Application)                           REF:   268

 

  1. A patient who has angina is taking nitroglycerin and long-acting nifedipine. The primary care NP notes a persistent blood pressure of 90/60 mm Hg at several follow-up visits. The patient reports lightheadedness associated with standing up. The NP should consult with the patient’s cardiologist about changing the medication to:
a. amlodipine (Norvasc).
b. isradipine (DynaCirc).
c. verapamil HCl (Calan).
d. short-acting nifedipine (Procardia).

 

 

ANS:  C

Verapamil and diltiazem are less likely to cause hypotension than nifedipine and related drugs, such as isradipine and amlodipine.

 

DIF:    Cognitive Level: Applying (Application)                           REF:   268

 

  1. An African-American patient who is obese has persistent blood pressure readings greater than 150/95 mm Hg despite treatment with a thiazide diuretic. The primary care NP should consider prescribing a(n):
a. angiotensin receptor blocker.
b. b-blocker.
c. ACE inhibitor.
d. calcium channel blocker.

 

 

ANS:  D

African-American patients are considered good candidates for calcium channel blockers to treat hypertension. Treatment with calcium channel blockers as monotherapy in African-American patients has proved to be more effective than some other classes of antihypertensive agents.

 

DIF:    Cognitive Level: Applying (Application)                           REF:   268

Additional information

Add Review

Your email address will not be published. Required fields are marked *